天晴速乐联合舒利迭治疗支气管哮喘-慢阻肺重叠综合征的可行性研究
Feasibility Study on Treating Bronchial Asthma with Spleen Intervention Syndrom
戴志辉 1冯长溪 1骆莹莹1
作者信息
- 1. 永康市第一人民医院 呼吸内科,浙江 永康 323100
- 折叠
摘要
目的 探讨噻托溴铵粉雾剂联合沙美特罗替卡松气雾剂治疗ACOS的疗效及安全性.方法 选取本院在2014年10月~2016年11月收治的76例ACOS患者,按照随机数字表法分为试验组和对照组,试验组给予噻托溴铵粉雾剂联合沙美特罗替卡松气雾剂治疗,对照组给予沙美特罗替卡松气雾剂治疗,比较2组患者临床疗效及不良反应情况.结果 试验组临床总有效率92.11%,对照组临床总有效率73.68%,2组比较差异具有统计学意义(Z=4.547,P<0.05);治疗后试验组ACT评分高于对照组,CAT评分低于对照组,差异具有统计学意义(P<0.05);试验组不良反应发生率为10.53%,对照组不良反应发生率为13.16%,2组比较差异无统计学意义(χ2=0.126).结论噻托溴铵粉雾剂联合沙美特罗替卡松气雾剂治疗支气管哮喘-慢阻肺重叠综合征疗效可靠,值得临床推广.
Abstract
Objective To investigate the efficacy and safety of tiotropium bromide aerosol combined with salmeterol in the treatment of ACOS. Methods 76 patients with ACOS were enrolled in this study from October 2014 to November 2016. They were divided into experimental group and control group according to the random number table method. The test group was given tiotropium bromide combined with salmeterol Casson aerosol treatment, the control group was given salmeterol tacrolone aerosol treatment, compared the two groups of patients with clinical efficacy and adverse reactions. Results The total effective rate was 92.11% in the experimental group and 73.68% in the control group, the difference was statistically significant (Z = 4.547, P<0.05). The ACT score of the test group was higher than that of the control group, the CAT score was lower than that of the control group, the difference was statistically significant (P<0.05); The incidence of adverse reactions in the test group was 10.53%, the incidence of adverse reactions in the control group was 13.16%,the difference was not statistically significant (χ2 = 0.126). Conclusion Tiotropium powder combined with salmeterol tegon aerosol in the treatment of bronchial asthma-chronic obstructive pulmonary syndrome is reliable and worthy of clinical practice.
关键词
噻托溴铵粉雾剂/沙美特罗替卡松气雾剂/ACOS/临床疗效Key words
tiotropium bromide aerosol/salmeterol texasone aerosol/ACOS/clinical efficacy引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据